Insider Trading Alert - MDVN, BWLD And LMAT Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 6, 2015, 74 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $199.44 to $8,899,995.42.

Highlighted Stocks Traded by Insiders:

Medivation (MDVN) - FREE Research Report

Bierly Rick, who is Chief Financial Officer at Medivation, sold 3,785 shares at $124.83 on May 6, 2015. Following this transaction, the Chief Financial Officer owned 16,226 shares meaning that the stake was reduced by 18.91% with the 3,785-share transaction.

The shares most recently traded at $121.68, down $3.15, or 2.59% since the insider transaction. Historical insider transactions for Medivation go as follows:

  • 4-Week # shares sold: 1,390
  • 12-Week # shares sold: 125,829
  • 24-Week # shares sold: 237,539

The average volume for Medivation has been 940,000 shares per day over the past 30 days. Medivation has a market cap of $9.5 billion and is part of the health care sector and drugs industry. Shares are up 21.32% year-to-date as of the close of trading on Wednesday.

Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. The company has a P/E ratio of 35.3. Currently, there are 11 analysts who rate Medivation a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDVN - FREE

TheStreet Quant Ratings rates Medivation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, notable return on equity, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Medivation Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

Medivation Founder Takes Helm at Axovant, Shares Spike

Second-Quarter Picks and Pans

How I'd Play Biotech Buyout Rumors

How I'd Play Biotech Buyout Rumors